Results 121 to 130 of about 3,776 (143)

A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors. [PDF]

Radiother Oncol
Barker CA, D'Angelo SP, Wasilewski G, Steckler AM, Lian M, Zhang Z, Chapman PB, Shoushtari AN, Ariyan CE.   +8 more
europepmc   +1 more source

Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus Talimogene Laherparepvec with Small Molecule Inhibitors. [PDF]

Viruses
Sotiriadis S, Beil J, Berchtold S, Smirnow I, Schenk A, Lauer UM.   +5 more
europepmc   +1 more source

Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy

JAAD Case Reports, 2018
Jason M. Rizzo, MD, PhD, Leslie A. Fecher, MD, May P. Chan, MD, Alison B. Durham, MD   +3 more
doaj   +1 more source

Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases

JAAD Case Reports, 2017
Jonathan T. Blackmon, Ratika Dhawan, MBBS, MPH, Toni M. Viator, RN, Nina L. Terry, MD, JD, Robert M. Conry, MD   +4 more
doaj   +1 more source

Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec. [PDF]

JAAD Case Rep
Che Y, Chong C, Limova M, Morris L, Reddy SA, Chang ALS.   +5 more
europepmc   +1 more source

Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma. [PDF]

Nat Commun
Joo V, Abdelhamid K, Noto A, Latifyan S, Martina F, Daoudlarian D, De Micheli R, Pruijm M, Peters S, Hullin R, Gaide O, Pantaleo G, Obeid M.   +12 more
europepmc   +1 more source

Talimogene laherparepvec

, 2017

core   +1 more source

Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors [PDF]

Cancer Immunology, Immunotherapy, 2017
Talimogene laherparepvec is a first-in-class intralesional oncolytic immunotherapy. In a recent Phase III trial (OPTiM), talimogene laherparepvec significantly improved durable response rate compared with subcutaneous granulocyte-macrophage colony ...
Reinhard Dummer, Christoph Hoeller, Olivier Michielin   +2 more
exaly   +2 more sources

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma [PDF]

Head and Neck, 2016
BACKGROUND: Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the oncolytic virus talimogene ...
Kevin Harrington, Howard Kaufman, Mohammed Milhem   +2 more
exaly   +2 more sources